早期t细胞前体白血病:诊断、治疗问题及自身临床病例描述

Q4 Medicine
Y. S. Korkina, T. Valiev, K. Kirgizov, S. Varfolomeeva
{"title":"早期t细胞前体白血病:诊断、治疗问题及自身临床病例描述","authors":"Y. S. Korkina, T. Valiev, K. Kirgizov, S. Varfolomeeva","doi":"10.21682/2311-1267-2022-9-4-107-113","DOIUrl":null,"url":null,"abstract":"   Early T-cell precursor leukemia (early T-cell precursor, ETP-ALL) is a new subvariant of acute lymphoblastic leukemia (ALL). Tumor blasts have a unique phenotype, including signs of both stem and myeloid cells. This fact significantly complicates differential diagnosis. Cytogenetic and molecular biological features of cells in ETP-ALL are the most important diagnostic criteria. Nowadays the leading scientific international groups of pediatric leukemia conduct researches to develop new treatment protocols for ETP-ALL or to optimize existing chemotherapy regimens by including targeted drugs (bortezomib, ruxolitinib, venetoclax). Currently, hematopoietic stem cell transplantation is a mandatory option in the treatment of ETP-ALL. Targeted drugs and CAR-T-cell (chimeric antigen receptor of T-cells) therapy are the most perspective ways of posable treatment. In this article there are summarized data on diagnosis and therapy and a description of a successful treatment of a patient with ETP-ALL.","PeriodicalId":52396,"journal":{"name":"Russian Journal of Pediatric Hematology and Oncology","volume":"22 10 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Early T-cell precursor leukemia: questions of diagnosis, treatment and description of own clinical case\",\"authors\":\"Y. S. Korkina, T. Valiev, K. Kirgizov, S. Varfolomeeva\",\"doi\":\"10.21682/2311-1267-2022-9-4-107-113\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"   Early T-cell precursor leukemia (early T-cell precursor, ETP-ALL) is a new subvariant of acute lymphoblastic leukemia (ALL). Tumor blasts have a unique phenotype, including signs of both stem and myeloid cells. This fact significantly complicates differential diagnosis. Cytogenetic and molecular biological features of cells in ETP-ALL are the most important diagnostic criteria. Nowadays the leading scientific international groups of pediatric leukemia conduct researches to develop new treatment protocols for ETP-ALL or to optimize existing chemotherapy regimens by including targeted drugs (bortezomib, ruxolitinib, venetoclax). Currently, hematopoietic stem cell transplantation is a mandatory option in the treatment of ETP-ALL. Targeted drugs and CAR-T-cell (chimeric antigen receptor of T-cells) therapy are the most perspective ways of posable treatment. In this article there are summarized data on diagnosis and therapy and a description of a successful treatment of a patient with ETP-ALL.\",\"PeriodicalId\":52396,\"journal\":{\"name\":\"Russian Journal of Pediatric Hematology and Oncology\",\"volume\":\"22 10 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-02-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Russian Journal of Pediatric Hematology and Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.21682/2311-1267-2022-9-4-107-113\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Russian Journal of Pediatric Hematology and Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21682/2311-1267-2022-9-4-107-113","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

早期t细胞前体白血病(Early T-cell precursor, ETP-ALL)是急性淋巴细胞白血病(acute lymphoblastic leukemia, ALL)的一种新亚型。肿瘤原细胞具有独特的表型,包括干细胞和骨髓细胞的迹象。这一事实显著地使鉴别诊断复杂化。细胞遗传学和分子生物学特征是ETP-ALL最重要的诊断标准。目前,国际领先的儿科白血病科学研究小组正在开展研究,以开发新的ETP-ALL治疗方案,或通过纳入靶向药物(硼替佐米、鲁索利替尼、维妥克拉克)来优化现有的化疗方案。目前,造血干细胞移植是治疗ETP-ALL的强制性选择。靶向药物和car - t细胞(t细胞的嵌合抗原受体)治疗是最有可能的治疗方法。在这篇文章中,总结了诊断和治疗的数据,并描述了一个成功的治疗患者的ETP-ALL。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Early T-cell precursor leukemia: questions of diagnosis, treatment and description of own clinical case
   Early T-cell precursor leukemia (early T-cell precursor, ETP-ALL) is a new subvariant of acute lymphoblastic leukemia (ALL). Tumor blasts have a unique phenotype, including signs of both stem and myeloid cells. This fact significantly complicates differential diagnosis. Cytogenetic and molecular biological features of cells in ETP-ALL are the most important diagnostic criteria. Nowadays the leading scientific international groups of pediatric leukemia conduct researches to develop new treatment protocols for ETP-ALL or to optimize existing chemotherapy regimens by including targeted drugs (bortezomib, ruxolitinib, venetoclax). Currently, hematopoietic stem cell transplantation is a mandatory option in the treatment of ETP-ALL. Targeted drugs and CAR-T-cell (chimeric antigen receptor of T-cells) therapy are the most perspective ways of posable treatment. In this article there are summarized data on diagnosis and therapy and a description of a successful treatment of a patient with ETP-ALL.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Russian Journal of Pediatric Hematology and Oncology
Russian Journal of Pediatric Hematology and Oncology Medicine-Pediatrics, Perinatology and Child Health
CiteScore
0.40
自引率
0.00%
发文量
36
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信